Evidence map›Paper›PMID 33148082›Full record

ArticleImmunotherapy2021

Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma.

Pragya Rai, Chan Shen, Joanna Kolodney, Kimberly M Kelly, Virginia G Scott, Usha Sambamoorthi

Abstract read
In one paragraph

Article in Immunotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Marginal health care expenditures for melanoma care in the United States.Journal of managed care & specialty pharmacy · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pragya RaiDepartment of Pharmaceutical Systems & Policy, West Virginia University School of Pharmacy, Morgantown 26506, WV.ORCID 0000-0002-7428-7273
Chan ShenDepartment of Surgery Chief, Division of Outcomes, Research & Quality Cancer Institute, Cancer Control Penn State Cancer Institute, Hershey 17033, PA.
Joanna KolodneyDepartment of Medicine, West Virginia University School of Medicine, Morgantown 26506, WV.
Kimberly M KellyDepartment of Pharmaceutical Systems & Policy, West Virginia University School of Pharmacy, Morgantown 26506, WV.ORCID 0000-0002-7006-3862
Virginia G ScottDepartment of Pharmaceutical Systems & Policy, West Virginia University School of Pharmacy, Morgantown 26506, WV.
Usha SambamoorthiDepartment of Pharmaceutical Systems & Policy, West Virginia University School of Pharmacy, Morgantown 26506, WV.ORCID 0000-0001-8311-1360

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI JUDITH FEINBERG · 2012 to 2026
$81.0M
NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overFemaleHealth ExpendituresHumansImmune Checkpoint InhibitorsLongitudinal StudiesMaleMedicareMelanomaMultimorbidityRetrospective StudiesUnited StatesImmune Checkpoint Inhibitorshealthcare expendituresimmune checkpoint inhibitorsipilimumabmedicare beneficiariesmelanomametastatic melanomamultimorbiditynivolumabolder patientspembrolizumab

Identifiers

PMID33148082
PMCPMC8008205

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.